354 related articles for article (PubMed ID: 19181468)
21. Management of local recurrence of colorectal cancer: the role of PET/CT.
Bamba Y; Itabashi M; Kameoka S
Abdom Imaging; 2011 Jun; 36(3):322-6. PubMed ID: 20661560
[TBL] [Abstract][Full Text] [Related]
22. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
23. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer.
Nakamoto Y; Sakamoto S; Okada T; Senda M; Higashi T; Saga T; Togashi K
AJR Am J Roentgenol; 2007 Jan; 188(1):257-67. PubMed ID: 17179375
[TBL] [Abstract][Full Text] [Related]
24. Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients.
Takenaka D; Ohno Y; Koyama H; Nogami M; Onishi Y; Matsumoto K; Matsumoto S; Yoshikawa T; Sugimura K
Eur J Radiol; 2010 Jun; 74(3):458-64. PubMed ID: 19398291
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of CT attenuation values of focal 18F-FDG avid breast lesions detected on whole-body PET-CT in postoperative breast cancer patients.
Plaza MJ; Collado-Mesa F; Bokhoor J; Alperin N; Yepes MM
Breast J; 2014; 20(3):235-42. PubMed ID: 24750508
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.
Grassetto G; Fornasiero A; Otello D; Bonciarelli G; Rossi E; Nashimben O; Minicozzi AM; Crepaldi G; Pasini F; Facci E; Mandoliti G; Marzola MC; Al-Nahhas A; Rubello D
Eur J Radiol; 2011 Dec; 80(3):828-33. PubMed ID: 20547020
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET/CT in the evaluation of POEMS syndrome.
Albertí MA; Martinez-Yélamos S; Fernandez A; Vidaller A; Narváez JA; Cano LM; Gamez C; Martinez-Matos JA
Eur J Radiol; 2010 Nov; 76(2):180-2. PubMed ID: 19581061
[TBL] [Abstract][Full Text] [Related]
29. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
[TBL] [Abstract][Full Text] [Related]
30. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
31. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
32. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
Comoretto M; Balestreri L; Borsatti E; Cimitan M; Franchin G; Lise M
Radiology; 2008 Oct; 249(1):203-11. PubMed ID: 18710963
[TBL] [Abstract][Full Text] [Related]
33. Can (18)F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?
Kang S; Ahn BC; Hong CM; Song BI; Lee HJ; Jeong SY; Lee SW; Lee J; Lee SJ
Nuklearmedizin; 2011; 50(3):116-21. PubMed ID: 21246162
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
[TBL] [Abstract][Full Text] [Related]
35. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
Chen Z; Li X; Li F; Ouyang Q; Yu T
Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
[TBL] [Abstract][Full Text] [Related]
36. Lesion concordance, image quality and artefacts in PET/CT: results of a multicenter study.
Stergar H; Krause BJ; Eschmann SM; Juergens KU; Kuehl H; Pfannenberg AC; Stollfuss J; Weckesser M; Bockisch A
Nuklearmedizin; 2010; 49(4):129-37. PubMed ID: 20514387
[TBL] [Abstract][Full Text] [Related]
37. Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT.
Manenti G; Cicciò C; Squillaci E; Strigari L; Calabria F; Danieli R; Schillaci O; Simonetti G
Eur J Radiol; 2012 Aug; 81(8):1917-25. PubMed ID: 21908120
[TBL] [Abstract][Full Text] [Related]
38. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.
Kruse V; Van de Wiele C; Borms M; Maes A; Pottel H; Sathekge M; Cocquyt V
Nuklearmedizin; 2014 Aug; 53(4):131-8. PubMed ID: 25100557
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
Grueneisen J; Sawicki LM; Wetter A; Kirchner J; Kinner S; Aktas B; Forsting M; Ruhlmann V; Umutlu L
Eur J Radiol; 2017 Apr; 89():14-19. PubMed ID: 28267530
[TBL] [Abstract][Full Text] [Related]
40. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
